Alectinib as a treatment option following recovery from crizotinib‑induced interstitial lung disease in patients with anaplastic lymphoma kinase‑positive advanced non‑small‑cell lung cancer
- Authors:
- Published online on: March 30, 2016 https://doi.org/10.3892/mco.2016.838
- Pages: 1085-1087
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Crizotinib is a tyrosine kinase inhibitor that displays antitumor activity against anaplastic lymphoma kinase (ALK)‑positive advanced non‑small‑cell lung cancer. However, crizotinib‑associated interstitial lung disease (ILD) has been reported as an infrequent, but potentially fatal complication. We herein describe the case of a 63‑year‑old male patient with ALK‑rearranged advanced lung adenocarcinoma. Chest computed tomography (CT) revealed extensive bilateral ground‑glass opacity and airspace consolidation with traction bronchiectasis on day 27 of crizotinib therapy. No signs of infection or left heart failure were identified and we considered the lesions to be consistent with crizotinib‑induced ILD. Following corticosteroid treatment and discontinuation of crizotinib, CT revealed improvement of ILD, but also showed regrowth of the tumor. Alectinib, a novel alternative ALK inhibitor, was initiated, and has been successfully continued, with neither disease progression nor recurrence of ILD. The present case indicates that alectinib may be considered as an alternative agent in cases of crizotinib‑induced ILD, irrespective of the pattern of ILD, i.e., a diffuse alveolar damage (DAD) or non‑DAD pattern, with careful observation.
